Six Insiders Adopt 10b5-1 Trading Plans for Up to 91,889 Shares
MNPR has more than doubled off its 52-week low of $29.18.
Summary
Six Monopar insiders, including the CEO and CFO, adopted 10b5-1 trading plans covering up to 91,889 shares. The cluster of plans is a governance red flag.
Key Events · Executive and Board Changes · MNPR
-
Six Insiders Adopt 10b5-1 Plans
Between May 26 and June 25, 2026, six insiders adopted Rule 10b5-1 trading plans: CEO Chandler Robinson (47,309 shares), CFO Quan Vu (615 shares), Executive Chairman Christopher Starr (16,800 shares), directors Kim Tsuchimoto (16,360 shares) and Raymond Anderson (9,425 shares), and Chief Medical Director Patrice Rioux (1,380 shares).
-
Aggregate Potential Sales of 91,889 Shares
Collectively, the plans cover up to 91,889 shares, representing approximately 1.4% of the 6.7 million shares outstanding. The plans terminate between December 2026 and July 2027.
-
Governance Red Flag
The simultaneous adoption of six insider trading plans is unusual and may signal coordinated selling intentions, creating a potential overhang on the stock.
Analysis · MNPR · Life Sciences
From May 26 to June 25, 2026, six insiders—the CEO, CFO, Executive Chairman, two directors, and the Chief Medical Director—adopted Rule 10b5-1 trading plans covering up to 91,889 shares in total. While these are pre-arranged, the sheer number of insiders adopting plans simultaneously raises a governance red flag that warrants attention. The plans permit sales through mid-2027, potentially creating an overhang on the stock.
At the time of this filing, MNPR was trading at $114.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $766.8M. The 52-week trading range was $29.18 to $124.82. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.